SCHEMBL39993

SCHEMBL39993

CC(C)(C)OC(=O)NCCCCC(=O)c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
STING1 Q86WV6 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA12 O43570 4/20 0.46
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA9 Q16790 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16215497 0.83 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1STING1KDM4EL3MBTL1
SCHEMBL29873554 0.83 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1STING1KDM4EL3MBTL1
SCHEMBL8278047 0.82 KMT2A (0.61) SMN1; SMN2ALDH1A1KMT2A
SCHEMBL10322699 0.80 L3MBTL1 (0.53) CYP3A4HDAC3HDAC4HDAC1HDAC7
SCHEMBL3719540 0.80 HDAC6 (0.57) SMN1; SMN2ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL24418337 0.80 CYP3A4 (0.49) CYP3A4TDP1CA12CA1CA2
SCHEMBL25937836 0.80 CYP3A4 (0.49) CYP3A4HDAC3HDAC4HDAC1HDAC7
SCHEMBL6957779 0.80 STK17B (0.49) CYP3A4SMN1; SMN2TDP1CA12CA1
SCHEMBL29263638 0.79 TDP1 (0.51) CYP3A4SMN1; SMN2TDP1CA12CA1
SCHEMBL38663029 0.78 GRM4 (0.45) SMN1; SMN2ALDH1A1STING1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11396501-B2 Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) 2022-07-26 US disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
WO-2019060860-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-03-28 WO disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396501-B2 Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same CXCR4, CXCL12, CXCR1 CYP3A4 2071/4885SMN1; SMN2 2758/4885ALDH1A1 1506/4885
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE IDO1, TPH1, AHR CYP3A4 503/4885SMN1; SMN2 3554/4885ALDH1A1 2066/4885
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CXCR4, CXCL12, CXCR1 CYP3A4 2071/4885SMN1; SMN2 2758/4885ALDH1A1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.